Researchtyk2psoriasistakedaphase 3
Takeda Reports Zasocitinib Achieves Rapid Skin Clearance
6.2
Takeda today announced Phase 3 results for zasocitinib (TAK-279), presented as a late-breaking abstract at the 2026 AAD Annual Meeting, showing rapid, durable skin clearance in adults with moderate-to-severe plaque psoriasis. About 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 versus 10–13% for placebo, with a safety profile consistent with Phase 2b findings.
Key Points
- 1Demonstrates rapid efficacy: ~69–70% achieved sPGA 0/1 at week 16 in two Phase 3 studies
- 2Indicates oral TYK2 inhibition rivals injectables for durable skin clearance and rapid onset
- 3Suggests clinicians will have a once-daily oral alternative; monitor safety signals and TEAE rates
Scoring Rationale
Phase 3, late-breaking AAD data provide high clinical credibility; limited impact for data-science-focused audiences.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
